Cannon CP, Braunwald E, McCabe CH, et al . Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–504. [OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4] Q In patients with an acute coronary syndrome (ACS), is standard dose pravastatin non-inferior to high dose atorvastatin for reducing death or major cardiovascular (CV) events? Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★☆ Internal medicine ★★★★★★☆ Cardiology ★★★★★★☆ ### ![Graphic][5] Design: randomised, placebo controlled trial (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 [PROVE IT-TIMI 22] trial). ### ![Graphic][6] Allocation: concealed.* ### ![Graphic][7] Blinding: blinded (clinicians and patients).* ### ![Graphic][8] Follow up period: mean 24 months. ### ![Graphic][9] Setting: 349 sites in 8 countries. ### ![Graphic][10] Patients: 4162 stable patients (mean age 58 y, 78% men) who were hospitalised for an ACS in the previous 10 days, were enrolled after a percutaneous revascularisation procedure (if planned), and had a total cholesterol concentration ⩽240 mg/dl (6.21 mmol/l) taken within the first 24 hours, or <6 months … [1]: {openurl}?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMoa040583%26rft_id%253Dinfo%253Apmid%252F15007110%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=10.1056/NEJMoa040583&link_type=DOI [3]: /lookup/external-ref?access_num=15007110&link_type=MED&atom=%2Febmed%2F9%2F5%2F144.atom [4]: /lookup/external-ref?access_num=000220682000005&link_type=ISI [5]: /embed/inline-graphic-1.gif [6]: /embed/inline-graphic-2.gif [7]: /embed/inline-graphic-3.gif [8]: /embed/inline-graphic-4.gif [9]: /embed/inline-graphic-5.gif [10]: /embed/inline-graphic-6.gif